Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation

Diabetes Research and Clinical Practice

Volumn 93, Issue 1, 2011, Pages 86-94

  Farvid, Maryam Sadat ^a   Homayouni, Fatemeh ^a   Amiri, Zohreh ^a   Adelmanesh, Farhad ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Micronutrients; Neuropathy; Type 2 diabetes

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; FOLIC ACID; GLUCOSE; MAGNESIUM; METFORMIN; PLACEBO; PYRIDOXINE; RIBOFLAVIN; SULFONYLUREA; THIAMINE; TRACE ELEMENT; ZINC;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CAPILLARY FLOW; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL INTAKE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNESIUM OXIDE; MALE; MICRONUTRIENTS; MIDDLE AGED; VITAMINS; ZINC SULFATE;

EID: 79960563100     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.03.016     Document Type: Article

References (33)

1. Boulton A.J., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962. [PMID: 15793206].
2. Shaw J.E., Zimmet P.Z., Gries F.A., Ziegler D. Epidemiology of diabetic neuropathy. Textbook of diabetic neuropathy 2003, 64-82. Thieme, Stuttgart/New York. F.A. Gries, N.E. Cameron, P.A. Low, D. Ziegler (Eds.).
3. Obrosova I.G., Minchenko A.G., Vasupuram R., White L., Abatan O.I., Kumagai A.K., et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes. 2003, 52:864-871. [PMID: 12606532].
4. Cameron N.E., Cotter M.A., Hohman T.C. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabetologia 1996, 39:172-182. [PMID: 8635669].
5. Askwith T., Zeng W., Eggo M.C., Stevens M.J. Oxidative stress, dysregulation of the taurine transporter in high-glucose-exposed human Schwann cells: implications for pathogenesis of diabetic neuropathy. Am J Physiol Endocrinol Metab 2009, 297:E620-E628. [PMID: 19602579].
6. Osawa T., Kato Y. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann N Y Acad Sci 2005, 1043:440-451. [PMID: 16037265].
7. Migdalis I.N., Triantafilou P., Petridou E., Varvarigos N., Totolos V., Rigopoulos A. Lipid peroxides in type 2 diabetic patients with neuropathy. Res Commun Mol Pathol Pharmacol 2005, 117-118:5-12. [PMID: 18426075].
8. Singh S.K., Sahay R.K., Krishna A. Oxidative stress in diabetic foot ulcer. Diabetes & metabolic syndrome. Clin Res Rev 2008, 2:109-113.
9. Ziegler D., Sohr C.G., Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004, 27:2178-2183. [PMID: 15333481].
10. Roldi L.P., Pereira R.V., Tronchini E.A., Rizo G.V., Scoaris C.R., Zanoni J.N., et al. Vitamin E (alpha-tocopherol) supplementation in diabetic rats: effects on the proximal colon. BMC Gastroenterol 2009, 9:88. [PMID: 19930636].
11. Tütüncü N.B., Bayraktar M., Varli K. Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study. Diabetes Care 1998, 21:1915-1918. [PMID: 9802743].
12. McCann V.J., Davis R.E. Serum pyridoxal concentrations in patients with diabetic neuropathy. Aust N Z J Med 1978, 8:259-261. [PMID: 211998].
13. Rodríguez-Morán M., Guerrero-Romero F. Low serum magnesium levels and foot ulcers in subjects with type 2 diabetes. Arch Med Res 2001, 32:300-303. [PMID: 11440788].
14. Pham P.C., Pham P.M., Pham S.V., Miller J.M. Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007, 2:366-373. [PMID: 17699436].
15. Bonnefont-Rousselot D. The role of antioxidant micronutrients in the prevention of diabetic complications. Treat Endocrinol 2004, 3:41-52. [PMID: 15743112].
16. Farvid M.S., Jalali M., Siassi F., Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 2005, 28:2458-2464. [PMID: 16186280].
17. Benzie I.F., Strain J.J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996, 239:70-76. [PMID: 8660627].
18. Feldman E.L., Stevens M.J., Thomas P.K., Brown M.B., Canal N., Greene D.A. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994, 17:1281-1289. [PMID: 7821168].
19. Brown M.J., Bird S.J., Watling S., Kaleta H., Hayes L., Eckert S., et al. Zenarest study Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care 2004, 27:1153-1159. [PMID: 15111537].
20. Martin C.L., Albers J., Herman W.H., Cleary P., Waberski B., Greene D.A., et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006, 29:340-344. [PMID: 16443884].
21. Lavery L.A., Murdoch D.P., Williams J., Lavery D.C. Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy. Diabetes Care 2008, 31:316-321. [PMID: 17977931].
22. Kimura J. Principles of nerve conduction studies. Electrodiagnosis in disease of nerve and muscle: principles and practice 1989, FA Davis, Philadelphia, pp. 79-93. 2nd ed.
23. Tavee J., Zhou L. Small fiber neuropathy: a burning problem. Cleve Clin J Med 2009, 76:297-305. [PMID: 19414545].
24. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. How far have we come?. Diabetes Care 2008, 31:S255-S261. [PMID: 18227494].
25. Smith A.G., Russell J., Feldman E.L., Goldstein J., Peltier A., Smith S., et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006, 6:1294-1299. [PMID: 16732011].
26. Armstrong A.M., Chestnutt J.E., Gormley M.J., Young I.S. The effect of dietary treatment on lipid peroxidation and antioxidant status in newly diagnosed noninsulin dependent diabetes. Free Radic Biol Med 1996, 21:719-726. [PMID: 8891676].
27. Hayee M.A., Mohammad Q.D., Haque A. Diabetic neuropathy and zinc therapy. Bangladesh Med Res Counc Bull 2005, 31:62-67. [PMID: 16967811].
28. Engelen W., Bouten A., De Leeuw I., De Block C. Are low magnesium levels in type 1 diabetes associated with electromyographical signs of polyneuropathy?. Magnes Res 2000, 13:197-203. [PMID: 11008927].
29. De Leeuw I., Engelen W., De Block C., Van Gaal L. Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm). Magnes Res 2004, 17:109-114. [PMID: 1531914].
30. Head K.A. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 2006, 11:294-329. [PMID: 17176168].
31. Wile D.J., Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010, 33:156-161. [PMID: 19846797].
32. Winkler G., Pál B., Nagybéganyi E., Ory I., Porochnavec M., Kempler P. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung 1999, 49:220-224. [PMID: 10219465].
33. Quattrini C., Tavakoli M., Jeziorska M., Kallinikos P., Tesfaye S., Finnigan J., et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 2007, 56:2148-2154. [PMID: 17513704].